High Diagnostic Value of $^{18}$F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature

Vikram Rao Bollineni$^{1,2}$, Sigmund Ytre-Hauge$^{3,4}$, Oksana Bollineni-Balabay$^5$, Helga Birgitte Salvesen$^{1,2}$, and Ingrid Salvesen Haldorsen$^{3,4}$

$^1$Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway; $^2$Center for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway; $^3$Department of Radiology, Haukeland University Hospital, Bergen, Norway; $^4$Department of Clinical Medicine, University of Bergen, Bergen, Norway; $^5$Department of Quantitative Economics, School of Business and Economics, Maastricht University, Maastricht, The Netherlands

The aim of this study was to evaluate the diagnostic performance of $^{18}$F-FDG PET/CT for the preoperative assessment of lymph node metastases (LNM) in endometrial cancer patients and for the assessment of endometrial cancer recurrence (ECR) after primary surgical treatment. Methods: A comprehensive search was performed on Pubmed/MEDLINE databases for studies reporting the diagnostic performance of $^{18}$F-FDG PET/CT for assessment of LNM and ECR published up to August 15, 2015. Twenty-one studies (13 for LNM and 8 for ECR) were included in the systematic review and meta-analysis. Pooled estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of the $^{18}$F-FDG PET/CT were calculated along with 95% confidence intervals (CIs). A summary receiver-operating-characteristics curve (SROC) was constructed, and the area under the SROC curve (AUC) was determined along with $Q^*$ index. Results: The overall pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and AUC (with 95% CI) of $^{18}$F-FDG PET/CT for detection of LNM were 0.72 (95% CI, 0.63–0.80), 0.94 (95% CI, 0.93–0.96), 10.9 (95% CI, 7.9–15.1), 0.36 (95% CI, 0.27–0.48), 39.7 (95% CI, 21.4–73.6), and 0.94 (95% CI, 0.85–0.99), respectively, whereas the corresponding numbers for detection of ECR were 0.95 (95% CI, 0.91–0.98), 0.91 (95% CI, 0.86–0.94), 8.8 (95% CI, 6.0–12.7), 0.08 (95% CI, 0.05–0.15), 171.7 (95% CI, 67.9–434.3), and 0.97 (95% CI, 0.95–0.98), respectively. The overall diagnostic accuracy ($Q^*$ index) in LNM and ECR were 0.88 and 0.93, respectively. Conclusion: $^{18}$F-FDG PET/CT has an excellent diagnostic performance for detecting LNM preoperatively and disease recurrence postoperatively in endometrial cancer patients.

Key Words: endometrial cancer; FDG; PET and CT

DOI: 10.2967/jnumed.115.170597

Endometrial cancer is the most common gynecologic malignancy in the developed countries (1). The prognosis is traditionally determined by clinical and histopathologic factors—that is, age, histologic type, grade, and stage of disease including assessment of cervical invasion, depth of myometrial invasion, lymph node spread, and distant metastases (2–4). The 5-y overall survival rate is generally favorable, around 80%. However, pelvic lymph node metastases (LNM) represents the most common site for extratumorine disease at primary treatment, and the 5-y survival rate is around 50% for this patient subgroup (5).

Currently, the final staging of endometrial cancer is based on histopathologic findings at primary surgery, which includes abdominal exploration, peritoneal cytology washing from the pelvis, hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy in selected patients presumed to have a high risk of disease spread (6–8). Routine systemic pelvic lymphadenectomy for early-stage endometrial cancer disease, although not well defined as a surgical technique, improves detection of LNM, but the procedure showed no survival benefit in 2 randomized clinical trials (9,10). Valid preoperative identification of patients with LNM who may benefit from lymphadenectomy is thus essential if futile surgical staging and unnecessary postoperative staging-related complications are to be minimized. If a noninvasive imaging technique could accurately preclude LNM preoperatively, lymphadenectomy procedures, currently with unproven clinical benefit for survival, could be safely circumvented. Hence, the development of noninvasive imaging methods enabling more accurate preoperative staging of endometrial cancer may facilitate better-tailored surgical decision making based on the selection of appropriate risk groups for LNM.

Conventional diagnostic imaging by transvaginal ultrasound, MRI, and CT provide detailed anatomic information, whereas functional or metabolic tumor characteristics may remain undetected. However, vigorous debate has challenged the use of anatomic assessments solely relying on tumor morphologic information, not taking into account functional tumor characteristics that may prove highly relevant for the clinical phenotype (11–13). In this regard, to better understand the tumor microenvironment, metabolic PET tracers such as $^{18}$F-FDG, in combination with CT, can overcome the limitations of morphologic imaging alone, because functional changes possible to detect by $^{18}$F-FDG PET/CT often precede morphologic changes detectable by conventional MRI or CT (14,15).
18F-FDG PET/CT has long been used successfully for evaluation of several malignancies including endometrial cancer (Fig. 1) (15,16). On the basis of a systematic review, here we report diagnostic indices of 18F-FDG PET/CT for the preoperative prediction of LNM and for the detection of disease recurrence after surgery with curative intent in endometrial cancer patients.

MATERIALS AND METHODS

Search Strategy

Because the study was not conducted on patients, no informed consent or ethical committee approval was needed. To identify all relevant publications, we performed systematic searches in the bibliographic databases PUBMED.com from inception to August 17, 2015. Search terms included controlled terms from Mesh in PUBMED.com using the following: 'FDG PET' in combination with 'Endometrial neoplasms'. The references of the identified articles were also searched for relevant publications.

Selection Process

One physician and 1 statistician reviewed each published article independently to determine the eligibility for inclusion in the meta-analysis and to extract information regarding clinical patient data and PET/CT characteristics. From the studies selected, data on first author, year of publication, number of patients included, study design (prospective or retrospective), patient age (mean/median), results from surgical International Federation of Gynecology and Obstetrics (FIGO) staging, percentage with nodal metastases, percentage with endometrioid subtype, 18F-FDG PET/CT technical characteristics, and numbers for diagnostic performance of 18F-FDG PET/CT (i.e., true-negatives, false-negatives, true-positives, false-positives, positive predictive value, and negative predictive value) were extracted and recorded. Any differences were resolved by consensus.

PET/CT studies that met the following criteria were included: first, studies that reported the diagnostic performance of 18F-FDG PET/CT in detecting LNM preoperatively or disease recurrence in endometrial cancer patients after primary surgery; second, clinical studies that included at least 10 patients; third, studies that applied 18F-FDG as a tracer on a dedicated device and were published after peer review. Studies on animals or in vitro studies, studies not available in full text or not written in English, and nonoriginal articles (e.g., reviews, editorials, letters, legal cases, interviews, case reports) were not evaluated systematically in this review.

Statistical Analysis

We performed standard methods recommended for meta-analysis of diagnostic test evaluations (17). Statistical analyses were performed using Meta-DiSc 1.4 software (developed by the unit of Clinical Biostatistics team of the Ramon y Cajal Hospital in Madrid, Spain) (18). We computed pooled measures for the following test indices of each study: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Further, the summary receiver-operating-characteristics curve (SROC) was constructed, and the area under the SROC curve (AUC) was determined.

A random-effects model was used for statistical pooling of the data. Pooled data were presented with 95% confidence intervals (CIs). The CI for diagnostic indices are exact—that is, they are based on the binomial distribution and hence are asymmetric. The I-square index was used to test for heterogeneity between studies. The AUC was calculated to measure the overall diagnostic performance of 18F-FDG PET/CT in detecting the LNM and endometrial cancer recurrence (ECR). The sensitivity and specificity for the single test threshold identified for each study were used to plot the SROC curve along with the Q* index representing an overall measure of the test’s discriminatory power.

RESULTS

Literature Search Results

The literature search yielded 58 references in PUBMED.com. In addition, 3 relevant recent articles on LNM in endometrial cancer and 1 in ECR that we were aware of were included in our database. The flow chart of the search and selection process is presented in Figure 2. Of a total of 62 articles, only 21 were eligible according to the criteria. Tables 1 and 2 summarize details for the included endometrial cancer studies of LNM and ECR by 18F-FDG PET/CT imaging, respectively.

Preoperative Detection of LNM

In our meta-analysis of LNM, 13 studies were included, comprising a total of 861 endometrial cancer patients. The overall
<table>
<thead>
<tr>
<th>Type</th>
<th>Patients (n)</th>
<th>Median age (y)</th>
<th>FIGO*</th>
<th>Purpose</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P (27)</td>
<td>236</td>
<td>65</td>
<td>IA-IVB (79%)</td>
<td>Evaluate value of SUVmax as tool in preoperative work-up of EC, with focus on MI, CI, FIGO, risk stratification, LNM.</td>
<td>PB sens 75%, spec 93%, PPV 60%, NPV 96%, and acc 90% for LNM. SUVmax significantly higher in high-risk EC (high FIGO, MI &gt; 50%, CI vs. no CI, LNM vs. no LNM) than low-risk EC.</td>
<td>Promise for distinguishing high- from low-risk EC and, indirectly, for determining aggressiveness.</td>
</tr>
<tr>
<td>P (25)</td>
<td>129</td>
<td>67</td>
<td>IA-IVB (76%)</td>
<td>Determine value of preoperative EC staging and relate imaging parameters to tumor characteristics.</td>
<td>Sens 85%, spec 92%, PPV 65%, NPV 98%, and acc 91% for LNM. SUVmax, MTV, and TLG were significantly related to deep MI, LNM, and high histologic grade.</td>
<td>Preoperative value for LNM detection; parameters relate to tumor aggression and help identify high-risk EC.</td>
</tr>
<tr>
<td>NA (31)</td>
<td>106</td>
<td>61</td>
<td>IA-IVB (88%)</td>
<td>Determine clinical value for pelvic LNM detection in EC.</td>
<td>PB sens 97%, spec 69%, PPV 75%, NPV 96%, and acc 90% for LNM.</td>
<td>Preoperative value for LNM detection in EC.</td>
</tr>
<tr>
<td>P (28)</td>
<td>76</td>
<td>63</td>
<td>IA-IVB (87%)</td>
<td>Evaluate parameter as predictor of LNM in EC.</td>
<td>Positive correlation: LNM and SUVmax (P = 0.003), MTV (P = 0.007), and TLG (P = 0.002) of PT. PB sens 79%, spec 98%, acc 95%, PPV 92%, and NPV 95% for LNM.</td>
<td>Potential for predicting LNM in EC patients.</td>
</tr>
<tr>
<td>R (32)</td>
<td>53</td>
<td>58</td>
<td>IA-IVB (83%)</td>
<td>Determine acc for LNM in EC.</td>
<td>PB sens 50%, spec 94%, PPV 40%, and NPV 96% for LNM.</td>
<td>High spec/NPV usefulness to select patients who may benefit from lymphadenectomy, minimizing surgical complication.</td>
</tr>
<tr>
<td>P (33)</td>
<td>46</td>
<td>56</td>
<td>I-IV (83%)</td>
<td>Determine clinical value for pelvic LNM detection in EC.</td>
<td>Sens 50% and spec 92% for detecting pelvic LNM.</td>
<td>Possible acc increase for LNM detection and reduction of false-positive results in preoperative EC patients.</td>
</tr>
<tr>
<td>P (22)</td>
<td>40</td>
<td>56</td>
<td>IA-IIIC (92%)</td>
<td>Evaluate acc for LNM detection in EC.</td>
<td>PB sens 50%, spec 86%, and acc 77% for LNM.</td>
<td>Preoperative value for LNM detection.</td>
</tr>
<tr>
<td>P (34)</td>
<td>37</td>
<td>61</td>
<td>IA-IVB (83%)</td>
<td>Determine acc for LNM detection in high-risk EC.</td>
<td>PB sens 78%, spec 100%, PPV 100%, NPV 93%, and acc 94% for LNM.</td>
<td>Accurate procedure for preoperative evaluation of pelvic LNM.</td>
</tr>
<tr>
<td>R (35)</td>
<td>33</td>
<td>54</td>
<td>NA (94%)</td>
<td>Evaluate diagnostic sens vs. MRI alone in EC patients and correlation between SUVmax and clinicopathologic tumor characteristics.</td>
<td>PB sens 80%, spec 96%, and acc 94% for LNM. Positive correlation between SUVmax of PT and lesion size (P = 0.001).</td>
<td>Diagnostic sens superior to CT or MRI alone.</td>
</tr>
<tr>
<td>R (36)</td>
<td>30</td>
<td>62</td>
<td>IA-IIIC (90%)</td>
<td>Evaluate acc of 18F-FDG PET/CT and PET/MR in assessment of LNM in EC.</td>
<td>PB sens 100%, spec 96%, and acc 97% for detecting LNM for both PET/MR and PET/CT. However, acc of PET/MR is superior to PET/CT in tumor staging (80% vs. 60%, P &lt; 0.04).</td>
<td>Integrated 18F-FDG PET/MR is superior to PET or MRI alone. Value in PT detection and nodal staging in EC patients.</td>
</tr>
<tr>
<td>R (37)</td>
<td>30</td>
<td>56</td>
<td>IA-IVB (63%)</td>
<td>Evaluate clinical usefulness for preoperative evaluation in EC.</td>
<td>PB sens 100% and spec 100% for detecting LNM.</td>
<td>Demonstration of high preoperative diagnostic performance in EC patients.</td>
</tr>
<tr>
<td>R (38)</td>
<td>26</td>
<td>61</td>
<td>IA-IVB (53%)</td>
<td>Determine clinical value for primary staging of high-risk EC patients.</td>
<td>PB sens 57%, spec 100%, PPV 100%, NPV 86%, and acc 88% for revealing LN involvement. For detecting distant metastases sens was 100%, spec 96%, PPV 87%, NPV 100%, and acc 97%.</td>
<td>Value in distant metastases detection in abdomen and extrabdominal regions with high diagnostic performance.</td>
</tr>
<tr>
<td>P (39)</td>
<td>19</td>
<td>66</td>
<td>IA-IVB (75%)</td>
<td>Determine sens and spec of preoperative 18F-FDG PET in detecting LNM in EC.</td>
<td>PB sens 67% and spec 94% for preoperative prediction of LNM disease in EC.</td>
<td>Preoperative 18F-FDG PET may be helpful with safe omission of lymphadenectomy in selected patients.</td>
</tr>
</tbody>
</table>

*FIGO stage followed by percentage endometrioid. P = prospective; EC = endometrial cancer; MI = myometrial invasion; CI = cervical invasion; PB = patient-based; sens = sensitivity; spec = specificity; PPV = positive predictive value; NPV = negative predictive value; acc = accuracy; MTV = metabolic tumor volume; TLG = tumor lesion glycolysis; NA = not available; R = retrospective; LN = lymph node.
<table>
<thead>
<tr>
<th>Type</th>
<th>Patients (n)</th>
<th>Median age (y)</th>
<th>FIGO*</th>
<th>Purpose</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>R (40)</td>
<td>127</td>
<td>52</td>
<td>IA–IVB (86%)</td>
<td>Determine feasibility for posttherapy surveillance in EC patients who showed NED.</td>
<td>Sens 100%, spec 88%, PPV 59%, and NPV 100% for detecting ECR in EC showing NED.</td>
<td>Effective detection of early recurrences in patients with EC showing NED after primary treatment.</td>
</tr>
<tr>
<td>R (41)</td>
<td>101</td>
<td>56</td>
<td>IA–IVB (NA)</td>
<td>Evaluate acc for identification of suspected ECR.</td>
<td>Sens 89%, spec 93%, PPV 94%, NPV 88%, and acc 91%.</td>
<td>High diagnostic yield in detecting recurrent EC.</td>
</tr>
<tr>
<td>R (42)</td>
<td>31</td>
<td>61</td>
<td>IA–IVB (NA)</td>
<td>Determine value of posttreatment imaging compared with CI and CA-125 in EC patients.</td>
<td>Overall sens, spec, and acc were 100%, 96%, and 97%, respectively, whereas for CI corresponding values were 46%, 87%, and 74%, respectively.</td>
<td>Posttreatment imaging is a more clinically useful modality than CI in evaluation of suspected ECR.</td>
</tr>
<tr>
<td>R (43)</td>
<td>31</td>
<td>53</td>
<td>IA–IVB (88.5%)</td>
<td>Evaluate acc for identification of suspected ECR after treatment.</td>
<td>Overall PB sens 100%, spec 84%, PPV 100%, NPV 97%, and acc 92%.</td>
<td>Demonstrated high diagnostic indices in detecting ECR.</td>
</tr>
<tr>
<td>R (44)</td>
<td>30</td>
<td>59</td>
<td>IA–IVB (90%)</td>
<td>Evaluate diagnostic acc, compared with PET alone, in diagnosis of suspected ECR.</td>
<td>Overall PB sens, spec, and acc were 93%, 93%, and 93% in detecting ECR, whereas with PET alone corresponding values were 80%, 80%, and 80%, respectively.</td>
<td>Diagnostic acc was superior to PET alone in detecting localization of sites of recurrence during follow-up.</td>
</tr>
<tr>
<td>R (45)</td>
<td>24</td>
<td>52</td>
<td>IA–IVB (81%)</td>
<td>Evaluate clinical impact of posttreatment imaging in surveillance of EC patients.</td>
<td>Overall sens 100%, spec 94%, PPV 96%, NPV 95%, and acc 100% of PET/CT imaging in detecting recurrence.</td>
<td>Highly effective in determining true recurrence in patients with suspected recurrence. Carries high impact on clinical decisions in most patients.</td>
</tr>
<tr>
<td>R (46)</td>
<td>21</td>
<td>62</td>
<td>IA–IVB (67%)</td>
<td>Clinical utility of postoperative $^{18}$F-FDG PET in ECR.</td>
<td>Sens, spec, and acc were 100%, 88%, and 93%, whereas sens, spec, and acc of combined CI (CT/MRI) were 84%, 85%, and 85%.</td>
<td>Superior to combined CI (CT/MRI) in detecting tumor recurrence.</td>
</tr>
<tr>
<td>P (47)</td>
<td>13</td>
<td>59</td>
<td>IB–IIIB (NA)</td>
<td>Determine diagnostic acc in detection of ECR.</td>
<td>Overall sens 93%, spec 100%, PPV 100%, NPV 92%, and acc 90% in detecting ECR.</td>
<td>Carries high diagnostic acc in determining ECR.</td>
</tr>
</tbody>
</table>

*FIGO stage followed by percentage endometrioid.
R = retrospective; EC = endometrial cancer; NED = no evidence of disease; sens = sensitivity; spec = specificity; PPV = positive predictive value; NPV = negative predictive value; NA = not available; acc = accuracy; CI = conventional imaging; PB = patient-based; PFS = progression-free survival; P = prospective.
The present meta-analysis yields high diagnostic performances of treatment and subsequent patient care. More accurately tailored primary surgical endometrial cancer accuracy was high. The pooled PLR was 10.9 (95% CI, 7.9–15.1), the pooled NLR was 0.36 (95% CI, 0.27–0.48), and the DOR was 39.7 (95% CI, 21.4–73.6).

The SROC representing a global summary score for the test performance yielded an AUC of 0.94 and a Q* value of 0.88 (Fig. 3C), indicating a relatively high level of overall accuracy.

### Detection of ECR

In the present meta-analysis for ECR, 8 studies comprising 378 patients have been included. The pooled sensitivity was 0.95 (95% CI, 0.91–0.98) (Fig. 4A), and the pooled specificity was 0.91 (95% CI, 0.86–0.94) (Fig. 4B). The pooled PLR was 8.8 (95% CI, 6.0–12.7), NLR was 0.08 (95% CI, 0.05–0.15), and DOR was 171.7 (95% CI, 67.9–434.3). The SROC curve for the 18F-FDG PET/CT in the detection of ECR yielded an AUC and Q* values of 0.97 and 0.93 (Fig. 4C), respectively, suggesting that the level of overall accuracy was high.

### DISCUSSION

Lymphadenectomy is currently commonly applied for lymph node staging in endometrial carcinoma as part of the surgical FIGO staging systems. However, noninvasive accurate lymph node staging in endometrial cancer by preoperative imaging seems advantageous compared with the more invasive nature of surgical lymph node staging, also with an unproven benefit from the procedure (9,10). Similar to other tumors, endometrial cancer has an increased tumor glucose metabolism and glycolysis rate, which makes it suitable for 18F-FDG PET/CT imaging (19–21). The present meta-analysis yields high diagnostic performances of 18F-FDG PET/CT for diagnosing LNM preoperatively. High diagnostic accuracy was also demonstrated for the procedure detecting ECR after primary surgical treatment. A high diagnostic performance clearly supports a role for 18F-FDG PET/CT imaging.

The pooled sensitivity for preoperative detection of LNM by 18F-FDG PET/CT is not good enough to reliably detect small tumors or micrometastatic disease. There is no documented threshold for lymph node size allowing PET/CT to correctly identify metastatic lymph nodes in endometrial cancer, although 1 study reported node-based sensitivities of 17% (4/24) for nodes of 4 mm or smaller, 67% (14/24) for nodes measuring 5–9 mm, and 93% (14/15) for nodes of 10 mm or larger (22). Similar figures with node-based sensitivities of 13%, 67%, and 100% in metastatic lymph nodes of 4 mm or smaller, 5–9 mm, and of 10 mm or larger, respectively, in endometrial cancer were reported in another study (23). It should, however, be kept in mind that although this meta-analysis found the overall sensitivity of 18F-FDG PET/CT to be moderate for the detection of LNM in endometrial cancer, it compares favorably with the reported sensitivities for LNM detection by conventional MRI and CT (24).

A high pooled specificity of 0.94 for metastatic lymph node detection by 18F-FDG PET/CT was found in this study, and it may be argued that this specificity is sufficiently high to safely omit a major surgical procedure in patients with low risk based on results from preoperative endometrial biopsy and preoperative imaging, reducing operative and postsurgical complications and costs (25). Furthermore, the present meta-analysis, showed that 18F-FDG PET/CT has a high PLR (10.9), pinpointing that 18F-FDG PET/CT findings suggesting metastatic lymph nodes are likely to be confirmed at surgical staging. The high diagnostic performance of 18F-FDG PET/CT for detecting endometrial cancer LNM is also justified by a high AUC of 0.94 in this meta-analysis. Interestingly, Kang et al. (26) reported almost identical figures for the diagnostic performance of 18F-FDG PET/CT for detecting LNM in cervical cancer, with a reported sensitivity of 0.73 (95% CI, 0.53–0.87) and specificity of 0.93 (95% CI, 0.86–0.97). Thus, 18F-FDG PET/CT seems to be equally feasible in endometrial and cervical cancer for lymph node staging, and 18F-FDG PET/CT may be particularly justified in endometrial and cervical cancer patients with high risk for disease spread, to identify metastatic lymph nodes preoperatively.

Several recent studies in endometrial cancer have demonstrated that preoperative primary tumor metabolic parameters have been associated with the presence of LNM. In a prospective study, Antonsen et al. (27) found a significantly higher SUV_max in patients with LNM than in those with no LNM (P = 0.04). Additionally, they found that SUV_max was significantly higher in patients with high FIGO stage, myometrial invasion, and cervical invasion. Furthermore, Crivellaro et al. (28) found strong
association between the presence of LNM and metabolic tumor volume in endometrial cancer. Recently, we demonstrated that the preoperative metabolic tumor volume cutoff value of 30 mL yielded sensitivity and specificity of 85% and 76% for LNM, respectively, suggesting that the metabolic tumor volume is a promising marker for LNM (25). In this regard, preoperative \(^{18}\)F-FDG PET/CT imaging of primary endometrial carcinomas may provide an adequate tool for prognostication and LNM detection that facilitate personalized patient care. However, additional prospective studies are required to define optimal cutoff values for predicting LNM based on \(^{18}\)F-FDG PET/CT metabolic parameters. Earlier studies describe measures for SUVs from a single region of interest, which does not represent the overall tumor profile. Therefore, advanced techniques such as the whole tumor voxel-by-voxel analysis may be a preferable approach to reduce operator dependence and capture more relevant and comprehensive measures for tumor microenvironment and heterogeneity.

The pooled sensitivity and specificity of \(^{18}\)F-FDG PET/CT for the detection ECR were 0.95 and 0.91, respectively, with an AUC in ROC analysis of 0.97 (95% CI, 0.95–0.99), all supporting a high level of overall diagnostic accuracy. Again, similar \(^{18}\)F-FDG PET/CT diagnostic performance indices were reported for detecting recurrent uterine cervical carcinomas, with a reported pooled sensitivity, specificity, and AUC of 0.92 (95% CI, 0.91–0.94), 0.84 (95% CI, 0.74–0.91), and 0.95, respectively (29). Thus, \(^{18}\)F-FDG PET/CT seems to perform equally well in the diagnosis of endometrial and cervical cancer recurrences, supporting a promising role for \(^{18}\)F-FDG PET/CT as a diagnostic tool for patients with suspected recurrence.

The findings in this study regarding \(^{18}\)F-FDG PET/CT and ECR must, however, be interpreted with care, considering that the studies report lack of histologic confirmation of all putative metastases based on \(^{18}\)F-FDG PET/CT, and they report variable follow-up of the cases considered nonmetastatic based on \(^{18}\)F-FDG PET/CT. Thus, some of the cases classified as correctly staged for ECR by \(^{18}\)F-FDG PET/CT may have been erroneously classified. This limitation shared by most published studies, including the studies on cervical cancer recurrence, is, however, hard to circumvent, because it seems unethical to perform biopsies of all suspected metastatic lesions in patients due to risk of complications. Furthermore, frequent \(^{18}\)F-FDG PET/CT follow-up scans are very expensive and imply unwanted radiation exposure for the patients.

Because both LNM and ECR studies exhibit interstudy heterogeneity, the SROC curve should be asymmetric (Supplemental Fig. 1 [supplemental materials are available at http://jnm.snmjournals.org] for both symmetric and asymmetric SROCs). Because all possible curves with the same true odds ratio and different degrees of heterogeneity would pass through the same point on the antidiagonal, the heterogeneity does not affect the Q* estimate but rather the shape of the curve and its standard errors. Walter et al. (30) noted that the AUC standard errors calculated under the homogeneity assumption provide a good approximation for heterogeneous studies. The approximation may be poor for extremely high DOR values (higher than 20), as is the case in both meta-analyses presented here (37.5 and 171.7 for LNM and recurrence, respectively). However, the bias in the homogeneity-based standard errors is mostly positive, and hence conservative, that is, can be overestimated, but rarely underestimated. Supplemental Figure 1 illustrates that the CIs of the asymmetric SROC are much narrower than those of the symmetric SROC, whereas the difference between the AUC estimates is negligible.

This meta-analysis has several limitations. First, positive result publication bias is a major concern, because nonsignificant or unfavorable study results tend to be discarded. However, we evaluated publication bias in our meta-analysis using funnel plot asymmetry, finding the funnel plots to be symmetric for both sensitivity and specificity pooling, implying no large bias in our study. Second, the current meta-analysis did not include region-by-region or node-by-node evaluation because this was not reported in most studies; however, this could have provided additional information. Third, not all included studies had a prospective study design. Fourth, the gold standard for confirmation of LNM or ECR, being histopathologic examination from biopsies, was not obtained from all the lesions reported in the studies. However, clinical follow-up data and results from renewed diagnostic imaging were recorded, and clinically putative lymph nodes metastases or ECR was used as a gold standard when histologic confirmation was missing.

CONCLUSION

Overall, \(^{18}\)F-FDG PET/CT demonstrated a high diagnostic performance in identifying LNM preoperatively and in detecting recurrence after endometrial carcinoma surgery with curative intent. Larger prospective studies are needed to validate this high diagnostic performance of \(^{18}\)F-FDG PET/CT in endometrial cancer and further assess patient subgroups with particular clinical benefit from applying this advanced imaging procedure.
DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. This study was supported by funding from the Norwegian Cancer Society. No other potential conflict of interest relevant to this article was reported.

REFERENCES

High Diagnostic Value of $^{18}$F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature

Vikram Rao Bollineni, Sigmund Ytre-Hauge, Oksana Bollineni-Balabay, Helga Birgitte Salvesen and Ingfrid Salvesen Haldorsen

Published online: January 28, 2016.
Doi: 10.2967/jnumed.115.170597

This article and updated information are available at:
http://jnm.snmjournals.org/content/57/6/879

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml